NCT00550537 2017-06-08
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
Clinical Trials
7 trialsNCT00499655 2017-03-29
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00530634 2015-10-29
Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT00541073 2011-05-17
Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00083083 2011-03-01
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00673569 2010-08-09
Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00161278 2008-07-30
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
University of Michigan Rogel Cancer Center
Phase 2 Terminated